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Huntington’s disease (HD) is a progressive and fatal neurodegenerative disorder caused by an expanded 
CAG repeat in the huntingtin gene. Although HD is monogenic, its molecular manifestation appears 
highly complex and involves multiple cellular processes. The recent application of high throughput 
platforms such as microarrays and mass-spectrometry has indicated multiple pathogenic routes. 
The massive data generated by these techniques together with the complexity of the pathogenesis, 
however, pose considerable challenges to researchers. Network-based methods can provide valuable 
tools to consolidate newly generated data with existing knowledge, and to decipher the interwoven 
molecular mechanisms underlying HD. To facilitate research on HD in a network-oriented manner, we 
have developed HDNetDB, a database that integrates molecular interactions with many HD-relevant 
datasets. It allows users to obtain, visualize and prioritize molecular interaction networks using HD-
relevant gene expression, phenotypic and other types of data obtained from human samples or model 
organisms. We illustrated several HDNetDB functionalities through a case study and identified proteins 
that constitute potential cross-talk between HD and the unfolded protein response (UPR). HDNetDB is 
publicly accessible at http://hdnetdb.sysbiolab.eu.
Huntington’s disease is an inherited neurodegenerative disorder that results from a trinucleotide (CAG) repeat 
expansion (>35) in the first exon of the huntingtin (HTT, IT15) gene1. Human HTT codes for a large protein 
of 3144 amino acids, which is ubiquitously expressed in various tissues and is present in several sub-cellular 
locations. Studies indicate that both loss of function of normal HTT as well as gain of function of mutant HTT 
contribute to neuropathological alterations in distinct regions of the brain2, 3. In the initial stages of HD, degen-
eration is detectable mainly in the striatum and cortex, whereas in later stages degeneration is also observed in 
other brain regions, such as the hypothalamus and hippocampus4, 5. Clinically, the disease is characterized by 
complex and variable symptoms that include movement disorders, psychiatric problems and cognitive decline2. 
Though HD is caused by mutation of a single gene, the disease development might involve a plethora of genes and 
processes6. Indeed, large variations in onset, severity and progression of HD suggest the existence of other influ-
ential molecular factors besides the mutation of HTT7–11. In order to identify genes that may modify disease onset 
and progression, genome-wide association and gene expression studies have been performed12, 13. Additionally, 
a large number of genes and proteins have been catalogued based on different types of experimental evidence6. 
Currently, identification of new targets, drugs and therapeutic strategies is at a crucial juncture, which can ulti-
mately contribute to a delayed onset or ameliorate progression of HD.
Despite considerable efforts, deciphering the precise pathological mechanisms underlying HD still requires 
further research. The large number of genes and the diversity of processes involved in the progression of 
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neurological diseases in general, and HD in specific, emphasizes the need for comprehensive approaches in addi-
tional to studies of individual genes14. Integrative network models can provide powerful tools for this. The mod-
els previously been applied to analyze a wide range of human diseases and have rapidly gained popularity15–17. 
The use of network-based approaches for examining HD is also motivated by the role of HTT. Several studies 
indicated that HTT interacts with a diverse array of cellular proteins18–21. These interacting partners play impor-
tant roles in various biological processes such as transcriptional regulation, vesicular transport and apoptosis 
as well as in signaling pathways such as MAPK, mTOR signaling and NOD-like receptor signaling22, 23. Thus, it 
is not surprising that large HTT-focused interaction networks have been derived by independent groups using 
yeast-two-hybrid (Y2H) screens or affinity purification mass spectrometry (AP-MS)20, 24–26. While being formi-
dable approaches, such studies require considerable expertise to assemble and analyze networks, which is a chal-
lenging task. In order to assist researchers in their pursuit to understand the disease mechanisms and to identify 
novel drug targets for HD, we have developed Huntington’s Disease Network DataBase (HDNetDB). It constitutes 
a versatile platform that integrates several levels of data and information ranging from protein-protein interac-
tions, regulatory interactions (microRNA-target gene and transcription factor-target gene), and gene expression 
to drug-target information about gene, gene ontology and pathway information to phenotype data pertaining to 
HD (Fig. 1). Besides being a central resource for integrated data and information, HDNetDB also equips users 
with several querying and visualization options for HD-related networks. HDNetDB is freely accessible at http://
hdnetdb.sysbiolab.eu and requires no login. To illustrate the potential of HDNetDB for network-oriented inves-
tigations, we describe an exemplary case study focusing on the unfolded protein response (UPR) in the context 
of HD.
Results
Case study: a potential connection between unfolded protein response (UPR) and Huntington’s 
disease. To illustrate the application of HDNetDB for network-based investigations, we examined the 
potential connection between HD and UPR, which is a complex intracellular pathway. UPR is activated upon 
accumulation of unfolded protein in the endoplasmic reticulum (ER). In mammalian cells, the UPR consists of 
three principal branches defined by signaling components located in the ER membrane: (i) ERN1 (Endoplasmic 
Reticulum To Nucleus Signaling 1) also referred to as IRE1 (inositol requiring enzyme 1), (ii) EIF2AK3 
(Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3) also referred to as PERK (protein kinase R-like ER 
kinase), and (iii) ATF6 (activating transcription factor 6). The main role of the UPR is to ensure homeostasis by 
increasing protein folding capacity within the ER, and by reduction of protein synthesis. If homeostasis cannot 
be re-established, persistent UPR activation can trigger cell death27. Although the UPR is well studied, its role in 
many diseases warrants further elucidation. This is also the case for HD, where different lines of investigation 
indicated a potential relevance of the UPR for the pathogenesis of HD28, 29.
Figure 1. Data and information integrated in HDNetDB. Many types of complementary data and information 
can be accessed, analyzed and visualized in HDNetDB. While the incorporation of generic data like the human 
interactome provides a backbone for unbiased network construction, the inclusion of many HD-specific data 
empower researchers to carry out network-oriented investigations targeting molecular processes in HD.
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To start our network-based investigations, we collected a small set of six key proteins that were reported to 
be involved in the UPR signaling pathway triggered by ER stress. Besides the three key signaling components 
mentioned above (ERN1, EIF2AK3, ATF6), we selected transcription factors X-Box Binding Protein 1 (XBP1) 
and DNA-damage-inducible transcript 3 (DDIT3), also known as CHOP. Both are downstream of ERN1 and 
EIF2AK3. Additionally, BCL2-associated X protein (BAX) was included, which modulates UPR by a direct inter-
action with ERN130, 31. It should be emphasized that numerous other proteins have been associated with the UPR, 
but we took only a small set for better illustration. Nevertheless, we would like to obtain a more comprehensive 
coverage of proteins associated with UPR and more importantly also of proteins that link the UPR to other pro-
cesses. Thus, we queried HDNetDB with the six proteins and obtained a set of 354 interacting proteins, which we 
refer to here as the UPR interactome (Table S1). The workflow and the UPR interactome generated by HDNetDB 
are presented in Fig. 2. In the network, the six queried proteins serve as “anchor” nodes.
We note that this example shows a common characteristic of network-based investigations: despite starting 
with a small number of anchor proteins, the retrieved networks are fairly large, especially for well-studied anchor 
proteins. This makes individual inspection of their components into a highly challenging and time-consuming 
task. To assist researchers here, HDNetDB offers a series of integrated tools, which enable rapid functional assess-
ment of retrieved networks and prioritization of network components for further investigation.
KEGG pathway enrichment analysis in UPR interactome. To gain insights into the functional com-
position of the retrieved networks, we performed statistical enrichment analysis based on KEGG pathways anno-
tations using the tool implemented on the Network page of HDNetDB. This type of analysis can identify those 
pathways curated in KEGG whose components are significantly overrepresented in the UPR interactome. Thus, 
we can verify whether we indeed obtained more proteins associated with UPR and we can identify other pro-
cesses that are linked to the UPR based on the extract interactions. Results of enrichment analysis are returned to 
the user of HDNetDB as a table listing the detected pathways along with the number of corresponding network 
proteins and their statistical significance (Fig. 3). For the UPR interactome, the pathway “Protein processing in 
the ER” achieved expectably the highest significance for overrepresentation (n = 41, FDR = 4.88E−23). Notably, 
apoptosis (n = 23, FDR = 5.48E−13) and cell cycle (n = 23, FDR = 2.29E−10) were also among the most significant 
KEGG pathways indicating a tight connection between the UPR and these processes within our network model 
of the UPR. Strikingly, we also found proteins associated with HD in the KEGG database (n = 20, FDR = 1.88E−5) 
to be strongly overrepresented within the UPR interactome supporting the link between UPR and HD. Besides 
statistical evaluation, HDNetDB enables the highlighting of proteins associated with the detected pathways and 
thereby facilitates the individual inspection of pathway components. Examples for this option can be shown in 
Fig. 3. Alternatively to KEGG annotations, users can carry out functional enrichment analyses based on Gene 
Ontology (GO) categories for molecular functions, biological processes and cellular compartments.
Linking the UPR interactome to mammalian phenotypes. Connecting molecular processes to 
phenotypes is a daunting task in biomedicine. An important help here is provided by extensive cataloging of 
Figure 2. HDNetDB workflow. HDNetDB retrieves the physical and regulatory interactions found for the 
queried genes or proteins, and generates a network. This is visualized by larger grey and smaller yellow nodes 
representing the input/query and interacting proteins, while red arrows and blue edges represent regulatory and 
protein-protein interactions, respectively. Subsequently, the network can be examined and filtered using various 
complementary datasets and tools integrated in HDNetDB.
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phenotypes observed for gene knockouts in model organisms. For research into human diseases, the systematic 
phenotype annotations of murine genotypes provided in the Mouse Genome Informatics (MGI) database are a 
valuable resource. This is also the case in our study of the UPR interactome. Using the relevant tool implemented 
in HDNetDB, the network was examined for possible enrichment of proteins associated with HD-relevant pheno-
types. Remarkably, we found that most of the selected phenotypes are highly overrepresented among the network 
components (Fig. 4). For instance, the most significant phenotype (n = 54; p = 5.8E-30) was “Decreased body 
weight”, which is a common characteristics of HD patients already in the early stage of disease32. Intriguingly, 
the UPR interactome is also strongly enriched in components linked to abnormal locomotor behavior (n = 31; 
p = 4.04E-14), which is a classical hallmark of HD. To our knowledge, such a connection between UPR and loss 
of motor control has not been put forward so far. All in all, the results of the phenotypic analysis carried out in 
HDNetDB suggest that the UPR interactome includes many genes whose knockout in mice lead to HD-relevant 
phenotypes. These genes can be readily identified interactively in HDNetDB (Fig. 4).
In silico screens with curated gene lists. Besides pathways information and functional or phenotypic 
annotation, HDNetDB includes curated HD-relevant gene lists, which can be used for examination of networks. 
Overrepresentation of curated genes among network components can readily be assessed. For the UPR network, 
HDNetDB identified several gene sets as significantly overrepresented (Supplementary Fig. S1). These include 
HD Therapeutic Target Genes (HDTTG) – a curated set of genes that were previously identified as potential 
therapeutic targets in HD6. Also, 63 HTT-interacting proteins were identified suggesting not only a functional 
but also a direct physical connection between UPR and (mutant) HTT. This is in line with previous findings that 
wild-type HTT is crucial for the integrity of the ER33. Since the poly-Q expansion results in a distinct binding 
behavior of mutant compared to wild-type HTT23, 34–36, the results of our analyses suggests that the HD-causing 
mutation might also have a direct impact on the functioning of the UPR through aberrant protein binding. In 
addition, we identified a large number of genes (n = 94) that have been genetically associated with neurological 
diseases, supporting a link between UPR and neuropathology in general. Importantly, users can carry out in 
silico screens based on their own uploaded gene lists, so they are not limited to the curated genes lists provided 
in HDNetDB.
Sequential filtering for prioritization of candidate genes. Besides the elucidation of the relevance of 
molecular processes for HD, prioritization of candidate genes for further study and for therapeutic intervention 
can be carried out efficiently in HDNetDB. Every network produced by application of a filtering procedure can 
be used as input for another filtering step. In this way, users can define the order and criteria for a sequential fil-
tering procedure in a flexible manner. Moreover, complementary data integrated in HDNetDB can be exploited 
for network-based gene selection – a strategy which has already been used effectively in molecular pharmacol-
ogy37. For illustration, we carried out step-wise filtering to identify components in the UPR interactome that 
are (i) differentially expressed, (ii) associated previously with HD and (iii) known drug targets. The underlying 
Figure 3. KEGG Pathway enrichment analysis. Results of enrichment analyses are returned as table listing 
pathways with significant overrepresentation among network proteins (right side). By a mouse click on a table 
row, components of the selected pathways are highlighted in the network as shown here for “Protein processing 
in endoplasmic reticulum” and “Huntington’s Disease”.
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motivation for these criteria was to discover proteins related to the UPR whose dysregulation can play a role in 
the pathogenesis of HD, and can be readily targeted by existing drugs. In the first step, the UPR interactome was 
filtered based on expression changes between human HD caudate nucleus and normal caudate nucleus, which are 
available in HDNetDB as one of many comparisons of HD-related gene expression data (Fig. 5a). This resulted in 
a network of 37 differentially regulated genes, of which 18 are up-regulated and 19 are down-regulated (Fig. 5b). 
In the next step, we filtered this network based on the criterion that the included components have been either 
directly or indirectly implicated in HD as described in Kalathur RK et al.6 (Fig. 5c). This led to the identification 
of network with 14 genes that are not only differentially expressed in HD but are also implicated in HD and thus 
may constitute a link between UPR and HD. Finally, we further filtered this network based on known drug-targets 
present in HDNetDB (Fig. 5d). Only four proteins remained after the sequential filtering that could possibly 
play key roles in linking HD and UPR, and can be targeted with existing drugs: histone deacetylase1 (HDAC1), 
jun proto-oncogene (JUN), solute carrier family 25 member 4 (SLC25A4) and 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR) (Fig. 5d).
HDAC1 is a component of the histone deactylase complex and plays an important role in regulation of gene 
expression. It can act as a molecular switch between neuronal survival and death by interacting with HDRP 
and HDAC3 respectively38. A recent study showed that targeting HDAC1 with HDAC inhibitors resulted in an 
improvement in HD related phenotypes in different HD model systems39. The second gene, JUN, is a transcrip-
tion factor and component of the AP-1 transcription complex that plays a key in role in neural development. 
Studies have also shown that there is a strong induction of JUN both at the gene and protein level in several 
human neurodegenerative diseases such as Alzheimer’s dementia40, 41, Parkinson’s disease42, 43 and amyotrophic 
lateral sclerosis44. The third known drug target we identified was SLC25A4 (ANT1), which is a member of a 
subfamily of solute carrier proteins that help in translocation of ADP from cytoplasm to mitochondrial matrix 
as well as of ATP from mitochondrial matrix to cytoplasm. In addition, SLC25A4 also regulates the mitochon-
drial permeability transition pore that initiates apoptosis. It has been speculated that increased expression of 
SLC25A4 following a brain injury has biphasic consequence: the initial repair of damaged cells and neurons by 
increasing ATP export but eventual destruction of damaged cells by apoptosis if the damage is beyond repair45, 46. 
The final gene (HMGCR) identified is an ER resident transmembrane glycoprotein and the rate-limiting enzyme 
for cholesterol synthesis. Perturbations of the cholesterol metabolism have been reported in HD models as well 
as in HD patients47. HMGCR levels are regulated in response to sterols by ubiquitin-proteasome system through 
ER-associated degradation (ERAD) pathway. As mutant HTT has been shown to impair ERAD in cellular models 
of HD, and thereby to interfere with protein homeostasis in the ER48, it is conceivable that an activated UPR might 
have an impact on the cholesterol synthesis in HD patients. Taken together, the reported findings indicate that 
the identified genes can provide attractive targets in the context of UPR and HD, although a more comprehensive 
evaluation is certainly warranted.
Figure 4. Phenotypic enrichment analysis. HD-relevant mammalian phenotypes are listed, for which a 
significant enrichment among components of the UPR interactome was detected. Highlighted phenotypes are 
“Abnormal Locomotor Behavior” and “Abnormal Learning Memory”. Red nodes represent the genes or proteins 
annotated with these HD-relevant phenotypes in MGI.
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Discussion
HD is a fatal neurodegenerative disease with no known cure. Although it is caused by mutation of a single gene, 
its molecular manifestation appears to be highly complex and includes numerous processes. To help researchers 
better cope with the molecular complexity of HD, we have developed HDNetDB. Its development was motivated 
by our own experiences in network-oriented analyses of HD. Although a large number of tools for analysis of 
interaction network exists (including our UniHI database49), they are generally generic and require laborious 
data handling to study selected aspects of a specific disease such as HD. HDNetDB can help to overcome these 
limitations. It is a flexible platform that is customized for HD research. It integrates different types of data rang-
ing from molecular interactions, drug-target information, HD associated genes and their expression in different 
model organisms and in humans.
HDNetDB was designed to provide easy access to the results of a query. The retrieved data are presented 
simultaneously on four pages (Proteins, Physical Interactions, Regulatory Interactions and Network) enabling the 
user to switch between different types of information (Fig. 6). The Proteins page gives an overview of the genes 
and proteins matching the query in the database. Proteins, which should not be included as anchor nodes in the 
generated network, can be excluded. In our case study, for instance, we excluded X-box binding protein 1 pseu-
dogene 1 (XBP1P1). It was found because one of its aliases is the same as the gene symbol of our query protein 
XBP. Such exclusion on the Proteins page will automatically update the network presented on the Network page. 
The Physical and Regulatory Interactions pages list all interaction partners found at the level of physical protein 
association or gene regulation for the queried genes and proteins. The sources from which each interaction has 
been retrieved are shown, and hyperlinks to these sources are provided, if available. In addition, different types of 
information regarding the individual interaction are given including the methods that were used for identification 
of the interactions as well as quality scores such as functional co-annotation and co-expression in human tissues. 
On both Interactions pages, options to download the full set of interactions are provided. Finally, the Network 
page displays a graphical visualization of the retrieved network. In addition to simple network visualization, a 
battery of tools for interactive network analysis is available on the side bar of the Network page. First, filtering of 
interactions can be carried out based on source, type, topology, experimental derivation and number of PubMed 
references attributed to the interaction. This allows the exclusion of interactions that might be considered less 
reliable by the user. For instance, setting the required number of PubMed reference to two reduces the net-
work interactions to those that have been reported in at least two publications. Alternatively, interactions from 
high-throughput experiments or computational prediction can be excluded for network reduction. Second, high-
lighting and filtering of network components can be performed on the basis of additional information integrated 
in HDNetDB such as HD-relevant gene expression data, gene sets, and drug target information. Since all filters 
Figure 5. Sequential filtering of UPR interactome. (a) Initial UPR network; (b) Network after filtering by 
differential expression in human HD caudate nucleus samples using the criteria log2 fold change ≥ +0.25 and 
≤−0.25; (c) Network of dysregulated components which have been indicated as potential therapeutic targets 
for HD; (d) Final network obtained after filtering using protein-drug target information (DrugBank). Red and 
green nodes indicate up and down regulated genes, respectively, and large grey nodes represent query proteins.
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can be applied sequentially, users of HDNetDB can easily develop and apply their own schemes for prioritization 
as illustrated in our case study. Third, the functional relevance of displayed networks can be explored through 
enrichment analysis. HDNetDB calculates the statistical significance of overrepresentation of network proteins 
among GO categories or KEGG pathways and returns a table with significantly enriched categories or pathways. 
The genes associated with a detected GO category or pathway can be highlighted in the network by clicking on 
the specific GO category or pathway in the table. Fourth, an equivalent enrichment analysis can be performed for 
mammalian phenotypes associated with the network components. These types of enrichment analysis can help 
to assess the functional relevance of the retrieved networks. Fifth, apart from providing functionalities based on 
data present in the database, the interface also enables users to map or filter networks based on their own gene 
list or gene expression data after uploading. In this manner, HDNetDB provides a readily extendable platform for 
data integration to the user. Lastly, the final network can be exported in a simple text tab-delimited file format, or 
as an image in PNG or PDF format.
Although many HD-relevant data have been integrated in HDNetDB, researcher might want to carry out 
analyses beyond the scope of HDNetDB. In this context, HDNetDB can serve as a primary resource for (filtered) 
interaction networks. Our recent meta-analysis of differential gene expression affecting the UPR in HD provides 
an example50. In that study, we used HDNetDB to define a UPR interactome (in the similar way as presented 
here), which was then downloaded and further scrutinized using the GSEA software to detect significant trends 
in expression changes. In addition, we downloaded interactions of apoptosis genes to detect and visualize links 
between UPR and apoptosis. For this purpose, we used the standalone Cytoscape software due to the large num-
ber of interactions, which prohibits a visualization via the web-application. Two possibilities of downloading 
HDNetDB interaction data in table format exist: (1) the (filtered) network from the Network page or (2) the listed 
interactions on the Physical and Regulatory Interactions pages. A word of caution here: The first option should 
only be used for networks with few interactions because of a time-consuming rendering process that underlies the 
generation of the table on the Network page. In contrast, the second option is much more efficient and provides 
rapid downloads for even large number of interactions. Alternatively, the full set of interaction data integrated in 
HDNetDB can be downloaded from the webpage.
Since HDNetDB integrates data from different dynamic sources, biannual updates are scheduled. 
Furthermore, we will continue to incorporate data and information with relevance for HD. These can include data 
from RNA-seq or genome-wide association studies, or information regarding the permeability of the blood-brain 
barrier for drugs. To facilitate the generation of high-confidence network, we plan to implement further options 
for filtering based on co-annotation and co-expression as well as on quality scores provided by some primary 
resources. An additional feature might be the visual indication of physical complexes in the network.
Figure 6. User interface of HDNetDB. After execution of the query, information about proteins and their 
interactions are shown and visualized on four different pages. The Network page provides additionally various 
tools for interactive analysis.
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To conclude, HDNetDB provides an array of tools for querying, analyzing and visualizing molecular interac-
tions. These tools will not only facilitate better understanding of biological processes, functions and pathways that 
are involved in HD pathogenesis but will also serve to identify novel molecular targets and the development of 
new therapeutic strategies in curing HD. Finally, we believe that HDNetDB can serve as a general prototype for a 
new generation of network-oriented resources that are customized towards specific diseases.
Methods
Database and architecture. HDNetDB is implemented using platform-independent and open-source 
software tools. Its architecture comprises two tiers: The database tier consists of a MySQL relational database 
management system. The application tier complies with an Java 2 Enterprise Edition J2EE architecture and 
includes Hibernate and Java DataBase Connectivity (JDBC) to connect to the back-end database, Data Access 
Object (DAO) to interact with the database and accessing data, and JavaServerPages (JSP) to generate web pages. 
The communication between client and the web application is carried out through Java servlets and JSP, employ-
ing an Apache Tomcat server with servlet container.
Molecular networks are visualized using Cytoscape Web library, which enables embedded representation of 
graphs into a webpage51. Performance of Cytoscape Web is a function of graph size, so performance decreases 
as the number of elements increases. To prevent the visualization tool from becoming unresponsive, certain 
automatic filtering and layout procedures have been implemented for larger networks (detailed in Supplementary 
Materials).
The HDNetDB database re-utilizes several components that have been developed previously for the Unified 
Human Interactome (UniHI) database49. In contrast to UniHI, which is a generic database for human molecular 
interactions and their annotation, HDNetDB is tailor-made for HD research and includes many additional data-
sets and functionalities. In particular, HDNetDB harbors molecular interactions, gene expression data, gene sets 
and phenotype information associated with HD and neurodegeneration.
Statistical network analyses. For interpretation of the functional relevance of displayed networks, we 
have implemented a tool performing enrichment analyses of network proteins for GO annotations52 and the 
public version of KEGG pathways53. The statistical enrichment is calculated using the hypergeometric distri-
bution. Enriched terms, along with their significance of enrichment displayed as p-values and false discovery 
rates (FDR)54, are returned to the browser in a tabular format. Computations are performed via Rserve (TCP/
IP server), which enables the use of R statistical software and several freely available Bioconductor packages at 
backend.
Data integrated in HDNetDB. Various types of data and information have been integrated in HDNetDB. 
Besides molecular interaction, HDNetDB includes gene expression and drug-target data as well as a diverse range 
of gene annotations and associations with relevance for neurodegeneration and HD.
Molecular interaction data. Molecular interactions in HDNetDB comprise both physical protein-protein 
interactions and regulatory interactions. Currently, HDNetDB integrates about 370000 unique interactions that 
were derived from large scale studies, literature curation or computational prediction. In particular, physical 
interactions identified for (mutant) HTT using high-throughput (HTP) Y2H assays or AP-MS were extracted 
from corresponding publications and merged into one dataset labeled as HTT-HTP20, 24, 25. In addition, we 
imported human protein-protein interactions from MDC55, CCSB56, HPRD57, DIP58, BIND59, BioGRID60, 
IntAct61, REACTOME62, COCIT63, ORTHO64, MINT(HOMOMINT)65, I2D (OPHID)66 and regulatory interac-
tions from the public version of TRANSFAC67, miRTarBase68 and HTRIdb69 via the UniHI database49. Number of 
proteins and interactions from each source are listed in Table 1.
Integrated gene expression data. HDNetDB includes various transcriptome datasets, which can be used 
to analyze molecular networks. They were obtained from microarray measurements of gene expression under-
taken for human HD brain or blood and controls samples as well as for different HD mouse models. An over-
view of currently included expression datasets is given in Table 270–76. Data were obtained from Gene Expression 
Omnibus and analyzed using the R statistical software and several Bioconductor packages. After preprocessing, 
log 2 fold changes for different comparisons were calculated from background-corrected and normalized signal 
intensities and uploaded to HDNetDB. In total, 13 comparisons of expression between HD samples and their 
corresponding control can be currently accessed. In addition to HD-associated gene expression data, HDNetDB 
also includes expression profiles for 19 different human tissues obtained from Symatlas77, 78.
Drug target information. To help rapidly identify known drug targets in molecular networks, relevant 
information from DrugBank79 was imported. Currently, HDNetDB holds information of about 4203 drugs that 
target about 2139 proteins. In total, 11793 drug target interactions are currently included. If available, the drug’s 
mode of action can be displayed.
Gene sets in the context of HD and neurodegeneration. Intersecting networks with informative gene 
sets can be useful in the prioritization of network components for follow-up studies. At present, five different gene 
sets associated with HD and neurodegeneration can be mapped onto networks and their statistical enrichment 
can be calculated in HDNetDB (Table S2): (i) HDTTG (Huntington’s Disease Therapeutic Target Genes) (n = 950) 
are comprised of therapeutic target genes described in Kalathur RK et al.6 and compiled from the HD Research 
Crossroads database. This gene list was manually curated and each included gene was scored based on exist-
ing experimental evidence for a disease-modifying effect. An extended list was recently published and will be 
included in future versions of HDNetDB80. (ii) HTT-interacting-proteins include 1016 genes whose corresponding 
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proteins were detected as directly or indirectly interacting with HTT. This gene set was derived by querying 
HDNetDB for HTT interactors. (iii) NDGA (Neurological Diseases Gene Association) consists of 2698 genes that 
have a genetic association with neurological diseases as indicated in the Genetic Association database81. The data 
were originally extracted from published papers on candidate genes and genome wide association studies. (iv) 
HDTM (Huntington’s Disease genes through Text Mining) was derived through text mining implemented in the 
GeneCards database82 using “Huntington’s disease” as a keyword search. The text mining returned 673 genes 
associated with HD. (v) NDMOD (Neurodegeneration Modifiers) is derived from independently compiled gene 
list comprising genetic modifies of neurodegeneration identified in various model systems. The list was created 
by review of published genetic screens undertaken in S. cerevisae, C. elegans and D. melanogaster models83. After 
mapping to Entrez Gene IDs of the corresponding human orthologs, 217 genes remained.
Source
Number of 
proteins
Number of 
interactions Type of interaction Methods Reference
HTT-HTP 925 1022 Physical protein interaction Y2H screens and AP-MS 20, 24–26
MDC-Y2H 1713 3340 Physical protein interaction Y2H screen 55
CCSB 3741 6821 Physical protein interaction Y2H screen 56
HPRD 12613 65227 Physical protein interaction Literature curation 57
BioGRID 14822 124035 Physical protein interaction Literature curation 58
BIND 11524 19352 Physical protein interaction Literature curation 59
DIP 3025 2925 Physical protein interaction Literature curation 85
IntAct 13611 37629 Physical protein interaction Literature curation 86
Reactome 5315 108867 Physical protein interaction Pathway curation 87
COCIT 3737 6580 Functional association Text mining 63
ORTHO 6056 62863 Physical protein interaction Computational prediction 64
HOMOMINT 6221 21863 Physical protein interaction Computational prediction + Literature curation 88
OPHID 7874 81677 Physical protein interaction Computational prediction 89
TRANSFAC 742 1554
Regulatory transcriptional 
interaction (Transcription factor-
based)
Literature curation 67
miRTarBase 2234 3565 Regulatory post-transcriptional interaction (microRNAs-based) Literature curation 90
HTRIdb 1634 2263
Regulatory transcriptional 
interactions (Transcription 
factor-based)
Literature curation 69
Table 1. Molecular interaction datasets integrated in HDNetDB. The source, number of imported proteins and 
interactions, type of interaction and methodology used for original identification of the interactions as well as 
the reference are listed.
# Species Tissue/Cell line Comparison of gene expression
Number 
of Arrays Reference
1 Human Caudate nucleus
Control_vs_HD
404 Hodges et al.70
Control_vs_Grade-1 HD
Control_vs_Grade-2 HD
Control_vs_Grade-3 HD
2 Mouse Whole brain
R6-1_18w_vs_wt_18w
18 Hodges et al.71R6-1_22w_vs_wt_22w
R6-1_27w_vs_wt_27w
3 Mouse Striatum Ctip2-/-_P0_vs_wt_P0 7 Arlotta et al.72
4 Mouse Striatum
R6-2_12 W_vs_wt_12W
26 Kuhn et al.73
CHL2-KI_22 M_vs_wt_22M
5 Mouse Striatum
YAC-128_12 M_vs_wt_12M
18 Becanovic et al.74
YAC-128_24 M_vs_wt_24M
6 Mouse Embryonic stem cells
mESC_CAG150_d4_vs_mESC_WT_d4
12 GSE9760
mESC_CAG150_d6_vs_mESC_WT_d6
7 Human Induced pluripotent stem cells (iPSCs) HD-iPSC_vs_Corrected HD-iPSC 16 An et al.
75
8 Human Whole blood HD-Whole-blood_vs_Control-whole-blood 14 Hu et al.76
Table 2. Gene expression datasets for human HD samples and mouse models that are integrated in HDNetDB. 
The comparisons that can be used for selection and filtering of networks are listed.
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Phenotypic information derived from mouse knock-out models. HDNetDB stores genotype-phenotype 
relations derived from mouse knock-out models for a selected set of phenotypes associated with HD. These were 
collected from the MGI database84 and include nervous system phenotype (MP:0003631; n = 2214), decreased 
body weight (MP:0001262; n = 1110), abnormal voluntary movement (MP:0003491; n = 904), abnormal locomo-
tor behavior (MP:0001392; n = 850), abnormal brain morphology (MP:0002152; n = 1042), abnormal synaptic 
transmission (MP:0003635; n = 444), abnormal learning/memory (MP:0001449; n = 413), emotion/affect behav-
ior (MP:0002572 abnormal; n = 346), abnormal eating/drinking behavior (MP:0002069; n = 450) and neurode-
generation (MP:0002229; n = 271). The list of mouse genes obtained for each phenotype are mapped to human 
orthologs and the corresponding human Entrez Gene IDs are stored in the HDNetDB.
HDNetDB web-interface: features and functions. As a starting point for a network-based analysis, 
HDNetDB can be queried for molecular interactions of single or multiple human genes or proteins. As input, 
identifiers such as gene symbols or Entrez Gene, UniProtKB and Ensembl IDs can be used. Besides identifiers for 
human genes or proteins, HDNetDB accepts identifiers from model organisms: yeast (Saccharomyces cerevisiae), 
worm (Caenorhabditis elegans), fly (Drosophila melanogaster) and mouse (Mus musculus). These are automati-
cally matched to the corresponding human orthologs to facilitate the practical use of HDNetDB for researchers 
working with HD model organisms. Accepted identifiers include Entrez Gene IDs for all model organisms, sys-
tematic names for yeast, WormBase IDs or gene symbols for worm, FlyBase IDs or gene symbols for fly and MGI 
identifiers or gene symbols for mouse.
The query generates four pages: Proteins, Physical Interactions, Regulatory Interactions and Network. The 
Proteins page lists found genes and proteins in the database. For all matches, the Entrez Gene, UniProtKB, 
Ensembl gene, RefSeq, and OMIM IDs as well as KEGG pathways (if available) are given along with hyperlinks to 
the resources. Furthermore, the original interaction datasets, in which the queried genes or proteins were found, 
are presented. By clicking on the corresponding Info button, gene ontology (GO) annotations are additionally 
displayed. The Physical and Regulatory Interactions pages show the found interactions and their sources. Detailed 
information including the method how the interaction was detected, corresponding PubMed references and con-
fidence scores based on GO co-annotations or co-expression can be accessed via a pop-up window through click-
ing the Info button. On the Network page, the generated network is displayed. The central nodes corresponding 
to query genes and proteins are highlighted as grey, large nodes in the default mode, while interacting partners 
are indicated by yellow, smaller nodes. Blue edges between nodes represent protein-protein interactions, whereas 
red arrows symbolize regulatory interactions with the given directionality. Using the implemented tools on the 
side-bar of the Network page, the network can be analyzed, sequentially filtered and exported.
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